Land: Jordanië
Taal: Engels
Bron: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)
Colistimethate 1.000.000 iu
شركة أدوية الحكمة - Hikma Pharmaceuticals
J01XB01
Colistimethate 1.000.000 iu
1.000.000 iu
1 Vial
Hikma Italia S.P.A (ايطاليا)
Colistin Hikma ® Colistimethate Sodium ACTION Colistimethate sodium is a cyclic polypeptide antibiotic derived from Bacillus polymyxa var. colistinus and belongs to the polymyxin group. The polymyxin antibiotics are cationic agents that work by damaging the cell membrane. The resulting physiological effects are lethal to the bacterium. Polymyxins are selective for Gram-negative bacteria that have a hydrophobic outer membrane. INDICATIONS Colistin Hikma is indicated in the treatment of the following infections where sensitivity testing suggests that they are caused by susceptible bacteria: • Treatment by intravenous administration of some serious infections caused by Gram-negative bacteria, including those of the lower respiratory tract and urinary tract, when more commonly used systemic antibacterial agents may be contra-indicated or may be ineffective because of bacterial resistance (nosocomial infections). • Treatment by inhalation of lung infection, caused by Pseudomonas aeruginosa, in patients with cystic fibrosis (CF). DOSAGE AND ADMINISTRATION Posology _Systemic Treatment:_ Colistin Hikma can be given as a 50ml intravenous infusion over a period of 30 minutes. Patients with a totally implantable venous access device (TIVAD) in place may tolerate a bolus injection of up to 2 million units in 10ml given over a minimum of 5 minutes. The dose is determined by the severity and type of infection and the age, weight and renal function of the patient. Should clinical or bacteriological response be slow the dose may be increased as indicated by the patient’s condition. Serum level estimations are recommended especially in renal impairment, neonates and cystic fibrosis patients. Levels of 10–15 mg/l (approximately 125-200 units/ml) colistimethate sodium should be adequate for most infections. A minimum of 5 days treatment is generally recommended. For the treatment of respiratory exacerbations in cystic fibrosis patients, treatment should be continued for up to 12 days. _Children and adults (including the el Lees het volledige document